IL-1β Sequence Guides Inflammatory Caspase Processing

Inflammatory caspases are often discussed as if their effects on cytokines follow a simple enzyme–substrate relationship: activation leads to cleavage, which leads to cytokine activity. The preprint The tetrapeptide sequence of IL-1β regulates its recruitment and activation by inflammatory caspases complicates that picture. It proposes that the amino-acid sequence immediately surrounding a cleavage site helps control whether IL-1β is recruited and processed into a biologically active form.

The report also broadens the potential cytokine-substrate range of non-canonical inflammasome caspases. Its findings distinguish direct IL-18 processing from a different outcome for IL-1β: human caspases-4 and -5 can cleave IL-18 to generate an active species, but cleave IL-1β at a site that yields a fragment predicted to be inactive. The work therefore emphasizes that detecting cleavage alone is not enough to infer cytokine function.

Study Background and Research Question

Canonical inflammasomes assemble in response to intracellular danger signals and activate caspase-1 (CASP1). Active CASP1 can process the precursors of IL-1β and IL-18, as well as gasdermin D (GSDMD). GSDMD cleavage releases a pore-forming fragment that contributes to cytokine release and pyroptotic cell death. In the non-canonical pathway, human CASP4 and CASP5, and mouse CASP11, respond to cytosolic lipopolysaccharide and can cleave GSDMD.

A central unresolved question is how inflammatory caspases recognize cytokine substrates, and whether non-canonical caspases directly process IL-1β or IL-18. Cleavage specificity is especially important because caspases can cut at multiple sites, and the resulting products may differ in activity. A protein fragment that appears after cleavage is not automatically a mature, receptor-active cytokine.

The authors address two connected questions: can active CASP4/5 directly process IL-18 and IL-1β, and does the local sequence around the established IL-1β cleavage site influence substrate recruitment and productive processing? The distinction matters for interpreting cytokine measurements in inflammasome experiments and for separating cytokine maturation from release during cell damage.

Key Innovation from the Reference Study

The principal conceptual advance is to treat the tetrapeptide sequence immediately upstream of the IL-1β cleavage site as a determinant of substrate handling, not merely as a passive recognition motif. The authors report that the P4–P1 sequence adjacent to the D116 cleavage site regulates recruitment and processing of IL-1β by inflammatory caspases. This offers a mechanistic explanation for why caspase activation, substrate cleavage, and formation of a bioactive cytokine should be considered distinct steps.

The second advance is the reported identification of direct cytokine substrates for non-canonical caspases. Active CASP4 and CASP5 cleave IL-18 to produce an active species. In contrast, CASP4/5 and mouse CASP11 cleave IL-1β at D27, producing a reported 27 kDa fragment predicted to be inactive and unable to signal through the IL-1 receptor. Thus, the same general class of proteases can have different functional consequences for two inflammatory cytokines.

Together, these observations argue for measuring cleavage position and biological activity, rather than using caspase activation or total cytokine release as a proxy for mature cytokine production. They also suggest that substrate sequence can contribute to the specificity of inflammatory signaling alongside the identity and activation state of the caspase.

Methods and Experimental Design Insights

The available study summary supports a three-part view of the experimental logic. First, the authors examined whether active non-canonical caspases could directly cleave cytokine substrates. Second, they identified distinct IL-18 and IL-1β processing outcomes, including the IL-1β cleavage at D27. Third, they connected processing at the canonical IL-1β D116 site to the identity of the adjacent P4–P1 sequence and to cytokine bioactivity. The reported inability of the D27-derived IL-1β fragment to signal through its receptor provides a functional distinction beyond a change in molecular size.

For researchers planning related experiments, the key design principle is to separate four readouts: caspase activation, substrate cleavage, release into the extracellular medium, and receptor-level activity. For example, cytokine in a supernatant could reflect processing followed by secretion, pore-mediated release, or cell lysis. A cleavage assay alone cannot resolve those possibilities. Pairing molecular readouts with a functional signaling assay can help determine whether the detected product is biologically active.

The supplied preprint record does not provide enough protocol detail to reproduce concentrations, incubation times, or assay-specific settings. Those should be taken from the complete methods and supplementary information rather than inferred from the abstract. The parameters below are therefore design considerations, not a substitute for the study’s experimental protocol.

Protocol Parameters

• Literature-grounded distinctions: Keep CASP1, human CASP4/5, and mouse CASP11 as separate experimental conditions; the study reports different cytokine-processing outcomes across these inflammatory caspases.
• Literature-grounded cleavage sites: Interpret IL-1β processing with attention to D27 and D116, since the report associates these sites with different products and functional implications.
• Workflow suggestion: Measure cytokine cleavage and receptor activity as separate outcomes; this helps distinguish generation of a fragment from production of a functional cytokine.
• Workflow suggestion: Pair cytokine measurements with GSDMD processing, cell viability, and release readouts when studying pyroptosis inhibition in macrophages or related cell models.
• Workflow suggestion: When testing sequence-dependent processing, compare matched IL-1β constructs that differ in the P4–P1 region and verify that expression and substrate availability are comparable.

Core Findings and Why They Matter

IL-18 is a direct substrate of CASP4 and CASP5

The study reports that active human CASP4 and CASP5 directly cleave IL-18 to generate an active form. This expands the potential direct cytokine-processing role of non-canonical inflammasome caspases beyond their established connection to GSDMD cleavage. It does not make CASP4/5 interchangeable with CASP1: the result instead supports evaluating cytokine processing by each caspase and substrate combination on its own terms.

IL-1β cleavage can be non-productive

CASP4/5 and CASP11 reportedly cleave IL-1β at D27, yielding a 27 kDa fragment predicted not to activate the IL-1 receptor. This is important for data interpretation. A cleavage band, or an overall change in IL-1β abundance, does not establish that a mature signaling-competent cytokine has been produced. The site and functional properties of the product matter.

Local sequence helps govern productive processing

For IL-1β processing at D116, the authors identify the P4–P1 tetrapeptide sequence as a regulator of recruitment and processing by inflammatory caspases. That result shifts attention from cleavage-site position alone to the surrounding substrate context. In practical terms, altered sequence context may affect enzyme–substrate engagement and the yield of bioactive product, which could help explain differences between caspases or experimental systems.

The findings are relevant to work on cytokine maturation, inflammasome signaling, and pyroptosis, but they do not imply that every caspase-dependent change in cytokine release reflects direct processing. Inhibition of IL-1β and IL-18 release, for example, can arise through effects on cytokine cleavage, pore formation, or cell death; these mechanisms require distinct measurements.

Comparison with Existing Internal Articles

The internal guide VX-765 workflows for caspase-1 research focuses on practical combinations of cytokine profiling, viability measurements, and time-resolved cell-death analysis. That assay-level advice complements this preprint: the paper adds a substrate-recognition mechanism and shows why release and bioactivity should not be treated as equivalent endpoints.

A separate overview of selective caspase-1 inhibition describes VX-765 and its active metabolite in CASP1-focused experiments. The distinction is important here because the preprint centers in part on CASP4/5/11. Results from a CASP1 inhibitor workflow should not be assumed to establish inhibition of those non-canonical caspases or to reproduce their substrate-specific effects.

Limitations and Transferability

The reference is a bioRxiv preprint posted in 2023 and was identified as not certified by peer review in the version cited. Its conclusions should therefore be interpreted as reported findings pending evaluation alongside subsequent literature. The condensed record available here also does not include detailed assay conditions, quantitative effect sizes, or the complete experimental validation, so it cannot support protocol-level replication on its own.

Transferability will depend on the biological system. The study distinguishes human CASP4/5 from mouse CASP11, making species choice a central design variable rather than a minor technical detail. Cell type, inflammasome activation state, cytokine precursor abundance, and the balance between processing and lytic release may also affect observed outputs. In particular, the reported cleavage outcomes do not establish that CASP4/5 or CASP11 dominate cytokine processing in every infected or inflamed tissue.

Finally, the mechanistic result about the IL-1β P4–P1 sequence does not by itself identify all determinants of caspase substrate selection. It supports sequence context as a regulatory factor, while leaving room for contributions from enzyme activation state, other substrate regions, and cellular organization. Follow-up studies should test whether the sequence-dependent behavior holds across relevant cell models and under endogenous expression conditions.

Research Support Resources

For CASP1-focused experiments related to cytokine release or pyroptosis, researchers can use VX-765, Caspase-1 inhibitor, potent and selective (SKU A8238) to support similar workflows. VX-765 is an orally absorbed prodrug metabolized to the active inhibitor VRT-043198; product information describes its use in studying CASP1-associated cytokine release and inflammation, including rheumatoid arthritis research. Because the reference study also examines CASP4/5/11, VX-765 should be treated as a CASP1-focused tool rather than a direct test of non-canonical caspase activity. Select assays and controls according to the caspase and biological endpoint under investigation.